EN DE
Watch Kangstem Biotech Co. Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Kangstem Biotech Co. Ltd (217730) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Kangstem Biotech Co. Ltd stock KRW 1,164, price KRW 1,712, that is 32.0% below the price, quality 26 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7217730001

KB Kangstem Biotech Co. Ltd logo Thin data Nov 16, 2026

Kangstem Biotech Co. Ltd

217730 · KQ

Expensive (fair value 32% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Revenue last quarter 38% below a year ago. 
Fair value 1,164 KRW · Overvalued 
Quality 26/100 
Weak Growth (revenue 5y −17.1 %/yr in KRW) 
Negative free cash flow 
Trails peers (3/8) 
Narrow moat 16/100
Thin data 
Estimate
Watch Kangstem Biotech Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

4,615 KRW 1,096 KRW Fair Value 1,164 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 1,096 KRW – 4,615 KRW · fair‑value band 872.64 KRW – 1,454 KRW · the 1,712 KRW price screens above the 1,164 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Kangstem Biotech Co. in your weekly email

Every Wednesday you see whether Kangstem Biotech Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases.

Show moreShow less

The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn's disease.

It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration.

In addition, the company offers stem cell culture media, including KSB-3 kit, a medium for culturing the human mesenchymal stem cell; and cell freezing and thawing platform. Further, it provides pharmaceutical contract manufacturing and development services.

Kangstem Biotech Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.

Stock analysis

Kangstem Biotech Co. Ltd (217730) currently trades at 1,712 KRW, while our estimate is 1,164 KRW, 32% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 872.64 KRW (bear) to 1,454 KRW (bull), the price of 1,712 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Kangstem Biotech Co. Ltd reported revenue of 3.6B KRW in FY2025 versus 12.4B KRW in FY2021, a compound −26.7%/yr. Reported net income was −10.5B KRW in FY2025.

Key figures

Market cap 160B KRW (≈ $120M) Micro · P/S ratio 57.8 · EPS (TTM) −123.04 KRW · Return on equity −47.9% · Return on assets (EBIT) −23.9% (5-year average) · Operating margin −944% · Revenue (TTM) 3.0B KRW · Revenue growth (YoY) −37.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 63% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −32%, 217730 screens richer than that median.

Fair Value

Bear 872.64 KRW Fair Value 1,164 KRW Bull 1,454 KRW
Price 1,712 KRW · Downside -32.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 12
Are margins and returns getting better?
Cashflow 14
Do the profits arrive as real cash?
Financial strength 76
Debt, balance sheet and risk of trouble
Investment 49
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 21
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 30
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−53.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−39.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−17.1%
Start year 2020 (pandemic). Over 10 years: +9.2% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−218.1% (2020) → −494.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

217730 screens overvalued: fair value 32% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Kangstem Biotech Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −32.0% · Below median
Profitability
Return on assets −12.9% · Above median
Growth and dividend
Revenue growth (quarter YoY) −37.7% · Bottom 25%
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.34× · Cheaper than median
P/S (12 months) 52.86× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 217730
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 217730
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs 217730
argenx SE ARGX $950.95 $908.40 −4% vs 217730
CSL Limited CSL A$199.55 A$186.49 −7% vs 217730
Moderna, Inc MRNA $215.27 $135.64 −37% vs 217730
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs 217730
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 217730
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs 217730
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 217730

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kangstem Biotech Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Kangstem Biotech Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/217730

Frequently asked questions

Is Kangstem Biotech Co. Ltd (217730) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 1,164 KRW versus a price of 1,712 KRW, about 32% lower (overvalued).
What is the fair value of 217730?
Our estimate for Kangstem Biotech Co. Ltd is 1,164 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 1,712 KRW.
What is the quality score of 217730?
Kangstem Biotech Co. Ltd has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kangstem Biotech Co. Ltd (217730)?
Our calculated price target is the estimate of 1,164 KRW (as of Nov 16, 2026). Cautious scenario 872.64 KRW, optimistic scenario 1,454 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Kangstem Biotech Co. Ltd stock forecast for 2026?
Our estimate puts fair value at 1,164 KRW, about 32% lower versus a price of 1,712 KRW (overvalued). Cautious scenario 872.64 KRW, optimistic scenario 1,454 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Kangstem Biotech Co. Ltd (217730)?
Kangstem Biotech Co. Ltd reported trailing-twelve-month revenue of about 3.0B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Kangstem Biotech Co. Ltd (217730)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kangstem Biotech Co. Ltd it is 1,164 KRW per share (as of Nov 16, 2026), against a price of 1,712 KRW.
Is Kangstem Biotech Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 217730 trades above its calculated fair value: price 1,712 KRW, fair value 1,164 KRW, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 217730?
No. The price is what the market pays today (1,712 KRW); the fair value is what the company's own numbers justify (1,164 KRW). For Kangstem Biotech Co. Ltd the two are 548.49 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Kangstem Biotech Co. Ltd worth?
The market values Kangstem Biotech Co. Ltd at about 160B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 1,712 KRW; our models calculate a fair value of 1,164 KRW per share.
What do the bullish and bearish scenarios say about 217730?
Our models span a range for Kangstem Biotech Co. Ltd: cautious scenario 872.64 KRW, base 1,164 KRW, optimistic 1,454 KRW per share (as of Nov 16, 2026, price 1,712 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kangstem Biotech Co. Ltd (217730)?
Balance-sheet figures for Kangstem Biotech Co. Ltd (as of Nov 16, 2026): return on equity −47.9%, debt of 0.03 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is 217730 from its 52-week high?
Kangstem Biotech Co. Ltd trades at 1,712 KRW, about 63% below its 52-week high of 4,615 KRW and 23% above the low of 1,397 KRW (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of 1,164 KRW is for.
Which stocks are comparable to Kangstem Biotech Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kangstem Biotech Co. Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price 1,712 KRW, calculated fair value 1,164 KRW (−32%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Kangstem Biotech Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kangstem Biotech Co. Ltd (217730)?
The closing price on Nov 16, 2026 was 1,712 KRW. Our estimate is 1,164 KRW, about 32% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kangstem Biotech Co. Ltd right now?
The price sits above even our optimistic bull case (1,454 KRW). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Kangstem Biotech Co. Ltd

How large is the market capitalisation of Kangstem Biotech Co. Ltd (217730)?
The market capitalisation of Kangstem Biotech Co. Ltd is 160B KRW (≈ $120M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kangstem Biotech Co. Ltd (217730)?
The price-to-sales ratio of Kangstem Biotech Co. Ltd is 57.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kangstem Biotech Co. Ltd (217730)?
Earnings per share at Kangstem Biotech Co. Ltd are −123.04 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Kangstem Biotech Co. Ltd (217730)?
The return on equity (ROE) of Kangstem Biotech Co. Ltd is −47.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kangstem Biotech Co. Ltd (217730)?
On an EBIT basis the return on assets of Kangstem Biotech Co. Ltd is −23.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kangstem Biotech Co. Ltd (217730)?
The operating margin of Kangstem Biotech Co. Ltd is −944% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kangstem Biotech Co. Ltd (217730)?
Revenue at Kangstem Biotech Co. Ltd is down 37.7% versus a year earlier (3y avg −39.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Kangstem Biotech Co. Ltd (217730) generate?
The free cash flow of Kangstem Biotech Co. Ltd is −12.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Kangstem Biotech Co. Ltd (217730) carry?
The net debt of Kangstem Biotech Co. Ltd is 5.8B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Kangstem Biotech Co. Ltd in the live analysis

One click puts Kangstem Biotech Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.